Japer Therapeutics Warrants
JSPRW
5 hedge funds and large institutions have $619K invested in Japer Therapeutics Warrants in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
17.87% more ownership
Funds ownership: 2.65% → 20.52% (+18%)
15% more capital invested
Capital invested by funds: $538K → $619K (+$80.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$13.1K |
| 2 |
ZA
Zazove Associates
Incline Village,
Nevada
|
+$11.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
1
Cowen and Company
New York
| $434K | +$13.1K | +72,125 | +3% |
|
2
Walleye Capital
New York
| $119K | – | – | – |
|
|
TCM
3
Tenor Capital Management
New York
| $50K | – | – | – |
|
|
ZA
4
Zazove Associates
Incline Village,
Nevada
| $12.8K | +$11.9K | +65,456 | New |
|
5
Walleye Trading
New York
| $2.82K | – | – | – |
|
JSPRW Hedge Fund Activity: Q2 2024 in Review
5 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2024, worth a combined $619K — up 15% from $538K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new JSPRW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Cowen and Company, adding an estimated $13.1K.
- 5 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2024, up from 4 in Q1 2024.
- Funds reported $619K of Japer Therapeutics Warrants stock for Q2 2024, up 15% quarter-over-quarter.
- 1 fund opened new Japer Therapeutics Warrants positions in Q2 2024 and 0 closed out, a net change of +1 holder.
- The largest Japer Therapeutics Warrants buyer in Q2 2024 was Cowen and Company, an estimated $13.1K added.
Based on aggregated 13F filings for Q2 2024.